Show simple item record

dc.contributor.authorvan Lenthe, M
dc.contributor.authorvan der Meulen, R
dc.contributor.authorOkell, L
dc.contributor.authorPiriou, E
dc.contributor.authorLassovski, M
dc.contributor.authorBakula, E
dc.contributor.authorBadio, C
dc.contributor.authorRoper, C
dc.contributor.authorBousema, T
dc.contributor.authorOuabo, A
dc.contributor.authorCibenda, D
dc.contributor.authorGrignard, L
dc.contributor.authorLanke, Kjerstin
dc.contributor.authorRao, B
dc.date.accessioned2020-01-08T15:46:58Z
dc.date.available2020-01-08T15:46:58Z
dc.date.issued2019-12-18
dc.date.submitted2020-01-07
dc.identifier.issn1475-2875
dc.identifier.doi10.1186/s12936-019-3057-7
dc.identifier.urihttp://hdl.handle.net/10144/619566
dc.description.abstractBackground Sulfadoxine–pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for programmes in the Democratic Republic of Congo (DRC). However, SP efficacy is threatened by drug resistance, that is conferred by mutations in the dhfr and dhps genes. The World Health Organization has specified that intermittent preventive treatment for infants (IPTi) with SP should be implemented only if the prevalence of the dhps K540E mutation is under 50%. There are limited current data on the prevalence of resistance-conferring mutations available from Eastern DRC. The current study aimed to address this knowledge gap. Methods Dried blood-spot samples were collected from clinically suspected malaria patients [outpatient department (OPD)] and pregnant women attending antenatal care (ANC) in four sites in North and South Kivu, DRC. Quantitative PCR (qPCR) was performed on samples from individuals with positive and with negative rapid diagnostic test (RDT) results. Dhps K450E and A581G and dhfr I164L were assessed by nested PCR followed by allele-specific primer extension and detection by multiplex bead-based assays. Results Across populations, Plasmodium falciparum parasite prevalence was 47.9% (1160/2421) by RDT and 71.7 (1763/2421) by qPCR. Median parasite density measured by qPCR in RDT-negative qPCR-positive samples was very low with a median of 2.3 parasites/µL (IQR 0.5–25.2). Resistance genotyping was successfully performed in RDT-positive samples and RDT-negative/qPCR-positive samples with success rates of 86.2% (937/1086) and 55.5% (361/651), respectively. The presence of dhps K540E was high across sites (50.3–87.9%), with strong evidence for differences between sites (p < 0.001). Dhps A581G mutants were less prevalent (12.7–47.2%). The dhfr I164L mutation was found in one sample. Conclusions The prevalence of the SP resistance marker dhps K540E exceeds 50% in all four study sites in North and South Kivu, DRC. K540E mutations regularly co-occurred with mutations in dhps A581G but not with the dhfr I164L mutation. The current results do not support implementation of IPTi with SP in the study area.en_US
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media LLCen_US
dc.relation.urlhttps://link.springer.com/article/10.1186/s12936-019-3057-7#author-informationen_US
dc.rightsWith thanks to the Malaria Journalen_US
dc.subjectParasitology
dc.subjectInfectious Diseases
dc.titleMarkers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemopreventionen_US
dc.typejournal-article
dc.contributor.departmentMSF OCA and MSF Londonen_US
dc.identifier.journalJournal of Malariaen_US
dc.source.volume18
dc.source.issue1
refterms.dateFOA2020-01-08T15:46:58Z


Files in this item

Thumbnail
Name:
vanLenth et al 2019 Markers of ...
Size:
1.480Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record